Agios Pharmaceuticals, Inc. (AGIO)
Healthcare • Biotechnology
StockNasdaqGSUnited StatesUS00847X1046
Kyvero is an independent information site. It is not affiliated with, endorsed by or sponsored by Agios Pharmaceuticals, Inc., and has no access to any account you may have with it. The name and the logo belong to their owners.
Price history
Daily prices in USD. Dividends, results and news are marked on the day they happened; click a day to see them.
Updated 12 Nov 2026 20:50. Information, not advice. Showing the last 12 months. Create a free account to see the whole history
Results
Earnings per share: estimate and reported
Estimate Reported: beat Reported: miss In line
Quarterly results
| Date | EPS estimate | EPS reported | Surprise | Result |
|---|---|---|---|---|
| 18 Feb 2027 08:00 | -1.10 | — | — | Upcoming |
| 05 Nov 2026 06:00 | -1.23 | -1.09 | +11.4% | Beat |
| 30 Jul 2026 06:00 | -1.66 | -1.69 | -1.5% | Miss |
| 29 Apr 2026 06:00 | -1.79 | -1.69 | +5.7% | Beat |
| 12 Feb 2026 06:00 | -1.94 | -1.85 | +4.9% | Beat |
| 30 Oct 2025 06:00 | -1.90 | -1.78 | +6.5% | Beat |
| 31 Jul 2025 06:00 | -1.75 | -1.93 | -10.0% | Miss |
| 01 May 2025 06:00 | -1.76 | -1.55 | +11.9% | Beat |
| 13 Feb 2025 06:00 | -1.63 | -1.74 | -6.8% | Miss |
| 31 Oct 2024 06:00 | 7.91 | -1.47 | -118.5% | Miss |
| 01 Aug 2024 07:00 | -1.61 | -1.69 | -4.9% | Miss |
| 02 May 2024 07:00 | -1.68 | -1.45 | +14.0% | Beat |
| 15 Feb 2024 07:00 | -1.64 | -1.72 | -5.0% | Miss |
| 02 Nov 2023 07:00 | -1.64 | -1.64 | -0.2% | In line |
| 03 Aug 2023 06:00 | -1.50 | -1.51 | -0.9% | In line |
| 04 May 2023 07:00 | -1.72 | -1.47 | +14.7% | Beat |
| 23 Feb 2023 07:00 | -1.53 | -1.66 | -8.4% | Miss |
| 03 Nov 2022 07:00 | -1.71 | -1.49 | +13.0% | Beat |
| 04 Aug 2022 07:00 | -1.78 | -1.68 | +5.5% | Beat |
| 05 May 2022 07:00 | -1.76 | -1.74 | +1.1% | Beat |
| 24 Feb 2022 07:00 | -1.57 | -1.77 | -12.6% | Miss |
| 03 Nov 2021 07:00 | -1.57 | -1.51 | +3.6% | Beat |
| 29 Jul 2021 07:00 | -1.28 | -1.39 | -8.1% | Miss |
| 29 Apr 2021 07:00 | -1.26 | -1.31 | -4.0% | Miss |
| 25 Feb 2021 07:00 | -1.31 | -1.41 | -8.0% | Miss |
| 05 Nov 2020 07:00 | -1.36 | -1.43 | -5.5% | Miss |
| 30 Jul 2020 07:00 | -1.36 | -1.31 | +3.7% | Beat |
| 30 Apr 2020 08:00 | -1.64 | -0.59 | +63.9% | Beat |
| 13 Feb 2020 07:00 | -1.68 | -1.60 | +4.9% | Beat |
| 31 Oct 2019 07:00 | -1.81 | -1.81 | -0.2% | In line |
| 01 Aug 2019 07:00 | -1.70 | -1.87 | -9.9% | Miss |
| 02 May 2019 07:00 | -1.75 | -1.59 | +9.2% | Beat |
| 14 Feb 2019 07:00 | -1.66 | -1.58 | +4.6% | Beat |
| 01 Nov 2018 07:00 | -1.62 | -1.63 | -0.7% | In line |
| 02 Aug 2018 07:00 | -1.55 | -1.19 | +23.1% | Beat |
| 04 May 2018 07:00 | -1.65 | -1.63 | +1.4% | Beat |
| 14 Feb 2018 07:00 | -1.61 | -1.81 | -12.6% | Miss |
| 01 Nov 2017 07:00 | -1.78 | -1.59 | +10.5% | Beat |
| 08 Aug 2017 07:00 | -1.57 | -1.78 | -13.5% | Miss |
| 04 May 2017 07:00 | -1.80 | -1.56 | +13.2% | Beat |
| 16 Feb 2017 07:00 | -1.51 | -1.34 | +11.4% | Beat |
| 03 Nov 2016 07:00 | -1.51 | -1.63 | -8.2% | Miss |
| 04 Aug 2016 07:00 | -1.30 | -1.47 | -12.8% | Miss |
| 05 May 2016 07:00 | -0.93 | -0.61 | +34.5% | Beat |
| 18 Feb 2016 07:00 | -0.53 | -1.08 | -102.2% | Miss |
| 05 Nov 2015 07:00 | -0.76 | -1.07 | -40.6% | Miss |
| 06 Aug 2015 07:00 | -0.57 | -0.85 | -48.4% | Miss |
| 07 May 2015 07:00 | -0.92 | -0.13 | +85.9% | Beat |
| 17 Feb 2015 07:00 | -0.53 | -0.76 | -42.7% | Miss |
| 07 Nov 2014 07:00 | -0.35 | 0.10 | +128.5% | Beat |
Annual results · USD
| Year | Revenue | Change | Net income | Net margin | EPS | EPS change | Free cash flow |
|---|---|---|---|---|---|---|---|
| 2025 | 54M | +48.0% | -412.8M | -764.0% | -7.12 | -161.2% | -387.3M |
| 2024 | 36.5M | +36.1% | 673.7M | 1,845.9% | 11.64 | +283.9% | -391.5M |
| 2023 | 26.8M | +88.4% | -352.1M | -1,312.6% | -6.33 | -49.6% | -314.6M |
| 2022 | 14.2M | — | -231.8M | -1,627.8% | -4.23 | — | -314.4M |
Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.
Prices by day, week and month
| Period | Opening price | High | Low | Closing price | Change | Volume | Dividend |
|---|---|---|---|---|---|---|---|
| 12 Nov 2026 | 32.56 | 32.63 | 31.56 | 31.79 | -3.14% | 306,260 | |
| 11 Nov 2026 | 31.99 | 33.12 | 31.53 | 32.82 | +3.34% | 844,700 | |
| 10 Nov 2026 | 31.00 | 31.89 | 30.48 | 31.76 | +1.21% | 1,005,400 | |
| 09 Nov 2026 | 29.32 | 31.45 | 28.93 | 31.38 | +6.70% | 1,341,900 | |
| 06 Nov 2026 | 28.99 | 29.80 | 28.46 | 29.41 | +4.03% | 1,281,200 | |
| 05 Nov 2026 | 31.19 | 31.19 | 27.57 | 28.27 | -9.91% | 2,551,300 | |
| 04 Nov 2026 | 32.09 | 32.09 | 30.56 | 31.38 | +0.58% | 1,106,300 | |
| 03 Nov 2026 | 30.20 | 31.64 | 30.06 | 31.20 | +4.17% | 684,900 | |
| 02 Nov 2026 | 30.95 | 31.42 | 29.83 | 29.95 | -1.96% | 1,912,500 | |
| 30 Oct 2026 | 31.43 | 33.00 | 29.80 | 30.55 | -17.94% | 3,094,300 | |
| 1,245 older periods: create a free account to see the whole history | |||||||
Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.
News
- Agios Pharmaceuticals, Inc. 2026 Q3 - Results - Earnings Call Presentation (opens in a new tab) SeekingAlpha · 10 Nov 2026 18:12
- Agios Pharmaceuticals, Inc. (AGIO) Q3 2026 Earnings Call Transcript (opens in a new tab) SeekingAlpha · 07 Nov 2026 09:44
- Agios Pharmaceuticals (AGIO) Stock Looks Pricey Despite Its 39% Run (opens in a new tab) Simply Wall St. · 07 Nov 2026 09:10
- Agios Pharmaceuticals Inc (AGIO) (Q3 2026) Earnings Call Highlights: Revenue Surges 4x on ... (opens in a new tab) GuruFocus.com · 06 Nov 2026 23:08
- Truist Securities Maintains Buy on Agios Pharmaceuticals, Lowers Price Target to $35 (opens in a new tab) Benzinga · 06 Nov 2026 13:45
- HC Wainwright & Co. Maintains Buy on Agios Pharmaceuticals, Raises Price Target to $62 (opens in a new tab) Benzinga · 06 Nov 2026 07:46
- Agios Pharmaceuticals, Inc. Q3 2026 Earnings Call Summary (opens in a new tab) Moby · 05 Nov 2026 22:05
- What Agios Pharmaceuticals (AGIO) Said on Its Q3 Earnings Call (opens in a new tab) MarketBeat · 05 Nov 2026 17:14
- Agios Pharmaceuticals (AGIO) Reports Q3 Loss, Beats Revenue Estimates (opens in a new tab) Zacks · 05 Nov 2026 12:15
- Agios Pharmaceuticals: Q3 Earnings Snapshot (opens in a new tab) Associated Press · 05 Nov 2026 11:40
- Agios Reports Third Quarter 2026 Financial Results and Provides Business Update (opens in a new tab) 05 Nov 2026 11:30
- Agios Pharmaceuticals Q3 2026 Earnings Call Transcript (opens in a new tab) Benzinga · 05 Nov 2026 10:16
- Agios Pharmaceuticals Q3 EPS $(1.09) Beats $(1.20) Estimate, Sales $55.385M Beat $53.208M Estimate (opens in a new tab) Benzinga · 05 Nov 2026 07:32
- Will FDA Review Delay Change Agios Stock Narrative (opens in a new tab) Simply Wall St. · 04 Nov 2026 08:18
- Agios Sinks 18% as FDA Delays Sickle Cell Drug Decision to 2027 Despite Being “Launch-Ready” (opens in a new tab) TIKR · 30 Oct 2026 15:56
Headlines link to the original articles of the publishers shown; Kyvero does not write, check or endorse them. Only the most relevant news about each company is kept. Information, not advice.
Key data
- Previous close
- 32.82 USD
- Market cap
- 1.9B
- Exchange
- NasdaqGS
- Country
- United States
- Sector
- Healthcare
- Industry
- Biotechnology
- Currency
- USD
Dividends
No dividends on record.
Why this score
| Part of the score | Points | Why |
|---|---|---|
| Business growth Yearly growth of revenue and of earnings per share. | 25.0 / 25 |
|
| Quality Return on equity, net margin and how stable the margins are. | 0.0 / 25 |
|
| Financial strength Net debt against operating earnings, interest cover and free cash flow. | 0.0 / 20 |
|
| Valuation Free cash flow yield and the P/E against its sector. | 0.9 / 15 |
|
| Analysts How far the analysts' average target is from today's price. | 10.0 / 10 |
|
- Score capped at 60: free cash flow was negative in two of the last three years
- The last full year was a loss
Growth profile: it pays no dividend, so it is scored on business growth, quality and financial strength. Based on 95% of the figures (grade A). Warnings take 6 points off.
Warnings take points off and some cap the score. In your account the score also considers how the share fits your portfolio. How the score works
Figures
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| P/E (forward) | -9.94× | Weak | 14.16× |
| Price / book | 1.94× | Fair | 3.5× |
| Price / sales | 13.49× | Weak | 3.33× |
| EV / EBITDA | -3.29× | Weak | 11.19× |
| Free cash flow yield | -13.9% | Weak | 2.1% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Gross margin | -150% | Weak | 54.9% |
| Operating margin | -297.7% | Weak | 5.8% |
| Net margin | -264.8% | Weak | 1.2% |
| Return on equity | -32.9% | Weak | 4.4% |
| Return on assets | -21.4% | Weak | 2.7% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Revenue growth / year | 56% | Good | 10.1% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Debt / equity | 0.03× | Good | 0.4× |
| Current ratio | 9.69× | Good | 2.64× |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Payout of earnings | 0% | Weak | 0% |
The reading follows general rules of thumb and each sector has its own norms: compare with the sector median when it is shown. Information, not advice.
Similar shares
Follow AGIO and get alerts
Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.